Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.

doi:10.1182/blood.2023021579

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.

Blood - 25 Jan 2024

Othman Jad, Tiong Ing S, O'Nions Jenny, Dennis Mike, Mokretar Katya, Ivey Adam, Austin Michael, Latif Anne-Louise, Amer Mariam, Chan Wei Yee, Crawley Charles, Crolla Francesca, Cross Joe, Dang Ray, Elliot Johnathon, Fong Chun Y, Galli Sofia, Gallipoli Paolo, Hogan Francesca, Kalkur Pallavi, Khan Anjum, Krishnamurthy Pramila, Laurie John, Loo Sun, Marshall Scott, Mehta Priyanka, Murthy Vidhya, Nagumantry Sateesh, Pillai Srinivas, Potter Nicola, Sellar Rob, Taylor Tom, Zhao Rui, Russell Nigel H, Wei Andrew H, Dillon Richard

Abstract excerpt

ABSTRACT: Assessment of measurable residual disease (MRD) by quantitative reverse transcription polymerase chain reaction is strongly prognostic in patients with NPM1-mutated acute myeloid leukemia (AML) treated with intensive chemotherapy; however, there are no data regarding its utility in venetoclax-based nonintensive therapy, despite high efficacy in this genotype. We analyzed the prognostic impact of NPM1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytarabine

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Neoplasm, Residual

Share to Nucleophosmin

Share to Prognosis

Share to Sulfonamides

Source

Open in PubMed

Identifiers

PMID: 37647641
DOI: 10.1182/blood.2023021579

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.PMID 37647641Read ↗

Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.Semantic proximity Read ↗

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.Semantic proximity Read ↗

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendationsSemantic proximity Read ↗

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.Semantic proximity Read ↗

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.Semantic proximity Read ↗

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.Semantic proximity Read ↗

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.Semantic proximity Read ↗

Prognostic and Therapeutic Implications of Measurable Residual Disease Detection Across Hematologic Malignancies: Clinical Impact on Relapse Prediction and Survival OutcomesSemantic proximity Read ↗

Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based TherapiesSemantic proximity Read ↗

Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?Semantic proximity Read ↗

Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO studySemantic proximity Read ↗

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.